Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Nicholas Chiorazzi, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT01110863
First received: December 10, 2009
Last updated: October 5, 2015
Last verified: October 2015
  Purpose
By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.

Condition
Chronic Lymphocytic Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects

Resource links provided by NLM:


Further study details as provided by Northwell Health:

Primary Outcome Measures:
  • Characterization of the Proliferating Compartment in B-CLL Patients and in Healthy Aging Subjects [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    B-CLL is a dx of accumulation rather than proliferation. Evidence for various forms of clonal evolution suggests that B-CLL clones may be more dynamic than previously assumed. A non-radioactive, stable isotopic labeling method to measure B-CLL cell kinetics in vivo. Subjects drank an aliquot of 2H2O daily for 84 days, and 2H incorporation into the deoxyribose moiety of DNA of their newly divided B-CLL cells, measured by gc/ms, during the labeling period. Birth rates were calculated from the kinetic profiles. Death rates were defined as the difference between calculated birth and growth rates.


Biospecimen Retention:   Samples With DNA
Blood cells, Bone Marrow

Estimated Enrollment: 90
Study Start Date: December 2005
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia

Detailed Description:
By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia (B-CLL) can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Chronic Lymphocytic Luekemia
Criteria

Inclusion Criteria:

  • 18 years of age,
  • Patients must be willing to contribute the required amount of blood without compromising their well being,
  • Participants must be willing to be contacted in the future.

Exclusion Criteria:

  • Pregnancy,
  • Patients who are known to be anemic, with a hemoglobin < 8,
  • Patients who are known to be infected with HIV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01110863

Locations
United States, New York
Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030
Sponsors and Collaborators
Northwell Health
Investigators
Principal Investigator: Nicholas Chiorazzi, MD Feinstein Institute for Medical Research
  More Information

Responsible Party: Nicholas Chiorazzi, Investigator, The Feinstein Institute for Medical Research, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT01110863     History of Changes
Other Study ID Numbers: 05-05-096  GAC # 0117 
Study First Received: December 10, 2009
Last Updated: October 5, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Northwell Health:
Chronic Lymphocytic Leukemia

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell

ClinicalTrials.gov processed this record on July 25, 2016